Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

作者: Ken Takezawa , Isamu Okamoto , Kazuto Nishio , Pasi A. Jänne , Kazuhiko Nakagawa

DOI: 10.1158/1078-0432.CCR-10-2798

关键词:

摘要: Purpose: EML4-ALK (echinoderm microtubule-associated protein–like 4 anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non–small cell lung cancer. The purpose of the present study to characterize mechanism malignant transformation by EML4-ALK. Experimental Design: We established NIH 3T3 cells that stably express variant 1 or 3 and examined signaling molecules function downstream Results: Forced expression induced marked activation extracellular signal–regulated kinase (ERK) STAT3, but not AKT. Inhibition ERK STAT3 resulted substantial attenuation proliferation expressing either EML4-ALK, suggesting these pathways cancer cells. specific ALK inhibitor TAE684 apoptosis accompanied both upregulation BIM, proapoptotic member Bcl-2 family, downregulation survivin, protein (IAP) EML4-ALK–expressing well H3122 human harboring endogenous Depletion BIM overexpression survivin each inhibited TAE684-induced apoptosis, contribute EML4-ALK–positive Furthermore, found be independently regulated pathways, respectively. Conclusions: inhibitor–induced is mediated resulting from inhibition Clin Cancer Res; 17(8); 2140–8. ©2011 AACR .

参考文章(40)
Ren-Yuan Bai, Tao Ouyang, Cornelius Miething, Stephan W. Morris, Christian Peschel, Justus Duyster, Nucleophosmin–anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway Blood. ,vol. 96, pp. 4319- 4327 ,(2000) , 10.1182/BLOOD.V96.13.4319
Andrea Morrione, Tomasz Skorski, Artur Slupianek, Mariusz A. Wasik, Margaret Nieborowska-Skorska, Liquan Xue, Stephan W. Morris, Miroslaw Majewski, Grazyna Hoser, Role of Phosphatidylinositol 3-Kinase-Akt Pathway in Nucleophosmin/Anaplastic Lymphoma Kinase-mediated Lymphomagenesis Cancer Research. ,vol. 61, pp. 2194- 2199 ,(2001)
Michael O. Hengartner, The biochemistry of apoptosis Nature. ,vol. 407, pp. 770- 776 ,(2000) , 10.1038/35037710
J. Fujimoto, M. Shiota, T. Iwahara, N. Seki, H. Satoh, S. Mori, T. Yamamoto, Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proceedings of the National Academy of Sciences of the United States of America. ,vol. 93, pp. 4181- 4186 ,(1996) , 10.1073/PNAS.93.9.4181
Kaoru Tanaka, Tokuzo Arao, Mari Maegawa, Kazuko Matsumoto, Hiroyasu Kaneda, Kanae Kudo, Yoshihiko Fujita, Hideyuki Yokote, Kazuyoshi Yanagihara, Yasuhide Yamada, Isamu Okamoto, Kazuhiko Nakagawa, Kazuto Nishio, SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. International Journal of Cancer. ,vol. 124, pp. 1072- 1080 ,(2009) , 10.1002/IJC.24065
Yupo Ma, Quan Lin, Yasushi Fujio, Keita Kunisada, Vasiliki Leventaki, Pamela Das, George Z Rassidakis, Cathy Cutler, L Jeffrey Medeiros, Raymond Lai, Hesham M Amin, Timothy J McDonnell, Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma Oncogene. ,vol. 23, pp. 5426- 5434 ,(2004) , 10.1038/SJ.ONC.1207703
Doris Polgar, Christina Leisser, Susanne Maier, Stephan Strasser, Beate Rüger, Markus Dettke, Maya Khorchide, Ingrid Simonitsch, Christa Cerni, Georg Krupitza, Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutation Research. ,vol. 570, pp. 9- 15 ,(2005) , 10.1016/J.MRFMMM.2004.09.011
Roberto Chiarle, William J Simmons, Honjying Cai, Girish Dhall, Alberto Zamo, Regina Raz, James G Karras, David E Levy, Giorgio Inghirami, Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target Nature Medicine. ,vol. 11, pp. 623- 629 ,(2005) , 10.1038/NM1249
David K Crockett, Zhaosheng Lin, Kojo SJ Elenitoba-Johnson, Megan S Lim, Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene. ,vol. 23, pp. 2617- 2629 ,(2004) , 10.1038/SJ.ONC.1207398
A. V. Galkin, J. S. Melnick, S. Kim, T. L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, Y. Wan, P. Ding, Y. Liu, F. Sun, P. G. Schultz, N. S. Gray, M. Warmuth, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 270- 275 ,(2007) , 10.1073/PNAS.0609412103